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Since the discovery and characterisation of this drug much work has been done on its bactericidal activity, mechanism of action, and development of resistance.1-4 It was noted that rifampicin, having a different chemical structure from isoniazid, has independent bactericidal action, and in wild strains of M tuberculosis, the incidence of rifampicinresistant mutants was appreciably lower, while the serum level attained on standard oral dosage was much higher than isoniazid.5 Moreover, the pattern of resistance development to rifampicin was reported to be a single step The purpose of this report is to present our observations on rifampicin resistance among strains of M tuberculosis from two different studies in which all rifampicin-resistant strains were found to be isoniazid-resistant as well.
Material and methods
The subjects of the first study were tuberculous patients in Pakistan. The study included hospitalised patients as well as cases from outpatient clinics. The majority of these cases were chronic, while some were newly diagnosed patients with no history of previous treatment. The patients were tested at the Pakistan Medical Research Council's Tuberculosis Research Center, Mayo Hospital, Lahore.
A total of 1063 strains from the same number of patients, after identification as niacin-positive M tuberculosis, were subjected to drug susceptibility testing by the standard proportion method using Lowenstein-Jensen (LJ) medium.8 The strains were tested against drugs listed in Table 1 .
The critical proportion for resistance-that is, the percentage of resistant bacteria among a test 927 Table 2 ). Only six of 13 whose previous drug treatment was known had histories of treatment with rifampicin.
In the CDC study, 34 strains were found to be resistant to rifampicin (1 ,ug/ml of 7H12 medium). All these were found to be resistant to isoniazid as well (0-2 ,ug/ml of 7H12 medium). There was 95 % agreement of these results with drug testing done independently on 7H10 medium on the same cultures at the Center for Disease Control.
Discussion
Rifampicin has been introduced only recently in Pakistan, and, due to its high cost, is not widely used, least of all among poor patients. Out of 21 rifampicinresistant cases, only six had a history of treatment Siddiqi, Aziz, Reggiardo, Middlebrook with rifampicin. It was interesting to note that all these rifampicin-resistant cases had had various combinations of other antituberculous drugs and had developed resistance against other drugs as well, but apart from isoniazid, there was no consistent pattern of resistance against any other drug. The second observation was drawn out of an altogether independent study concerned with development of a radiometric method for drug susceptibility determination. The cultures were from patients' sputa which were submitted from all over the United States. Since this was a comparative study of two different methods of drug susceptibility testing, no information is available concerning the past history of treatment of these patients. However, it is interesting to note that all the 34 rifampicin strains were consistently resistant to isoniazid while this consistency was not observed in the case of any other drug.
In any event, with two different methods of testing for two quite different patient populations, it was interesting to find all rifampicin-resistant cases also to beyielding strains resistant to 0-2 ,ug isoniazid/ ml medium. This observation has some clinical significance. It 
